- Home
- SLN vs IHRT Comparison
SLN vs IHRT Comparison
Compare SLN & IHRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- IHRT
- Stock Information
- Founded
- SLN 1994
- IHRT N/A
- Country
- SLN United Kingdom
- IHRT United States
- Employees
- SLN N/A
- IHRT N/A
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- IHRT Broadcasting
- Sector
- SLN Health Care
- IHRT Consumer Discretionary
- Exchange
- SLN Nasdaq
- IHRT Nasdaq
- Market Cap
- SLN 352.2M
- IHRT 289.7M
- IPO Year
- SLN N/A
- IHRT 2019
- Fundamental
- Price
- SLN $5.12
- IHRT $2.33
- Analyst Decision
- SLN Strong Buy
- IHRT Buy
- Analyst Count
- SLN 4
- IHRT 3
- Target Price
- SLN $61.50
- IHRT $3.00
- AVG Volume (30 Days)
- SLN 460.0K
- IHRT 894.2K
- Earning Date
- SLN 03-11-2025
- IHRT 02-27-2025
- Dividend Yield
- SLN N/A
- IHRT N/A
- EPS Growth
- SLN N/A
- IHRT N/A
- EPS
- SLN N/A
- IHRT N/A
- Revenue
- SLN $21,773,221.00
- IHRT $3,803,046,000.00
- Revenue This Year
- SLN N/A
- IHRT $6.16
- Revenue Next Year
- SLN $104.98
- IHRT N/A
- P/E Ratio
- SLN N/A
- IHRT N/A
- Revenue Growth
- SLN N/A
- IHRT N/A
- 52 Week Low
- SLN $4.82
- IHRT $0.81
- 52 Week High
- SLN $27.72
- IHRT $3.04
- Technical
- Relative Strength Index (RSI)
- SLN 25.52
- IHRT 60.58
- Support Level
- SLN $4.82
- IHRT $1.81
- Resistance Level
- SLN $7.87
- IHRT $2.22
- Average True Range (ATR)
- SLN 0.62
- IHRT 0.15
- MACD
- SLN -0.01
- IHRT 0.04
- Stochastic Oscillator
- SLN 9.20
- IHRT 96.33
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.
About IHRT iHeartMedia Inc.
iHeartMedia Inc is a United States-based diversified media and entertainment company. The company operates through the segments of the Multiplatform Group, the Digital Audio Group, and the Audio & Media Services Group. The company derives prime revenue from the Multiplatform Group segment which includes the company's Broadcast radio, Networks and Sponsorships, and Events businesses. The Digital Audio Group segment includes all of the company's digital businesses, including podcasting; and the Audio & Media Services Group includes Katz Media Group, a full-service media representation business, and RCS Sound Software, a provider of scheduling and broadcast software and services.